Alexander Thompson

Derek Archila

Gavin Clark-Gartner

Gregory Renza

Laura Chico

Michael Yee

Rami Katkhuda

Trevor Allred

- **Viridian Therapeutics** has priced an underwritten public offering of **11,425,000 shares** of common stock at **$22 per share**, expected to raise approximately **$251 million** before expenses.  **[1590750_860cb8c8c3a3456bb4dd65048da86788]** 
- The proceeds from this offering will fund commercial launch activities for its thyroid eye disease (TED) treatments **veligrotug** and **VRDN-003**, research and development, working capital, and general corporate purposes.  **[1590750_860cb8c8c3a3456bb4dd65048da86788]** 
- The company also commenced an offering of Series B non-voting convertible preferred stock, which can be converted into common stock at a rate of **1 preferred share to 66.67 common shares**.  **[1590750_860cb8c8c3a3456bb4dd65048da86788]** 
- Despite strong recent stock momentum and positive analyst sentiment, Viridian faces significant financial challenges, including operating losses with an operating margin of approximately **-121,831%** and a negative three-year revenue growth rate of **-74.8%**.  **[1590750_860cb8c8c3a3456bb4dd65048da86788]**

Viridian Therapeutics, Inc.\DE (VRDN)